Tango Therapeutics (TNGX) Cash & Equivalents (2020 - 2026)

Tango Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $157.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 170.11% year-over-year to $157.8 million in Q1 2026; TTM through Mar 2026 was $157.8 million, a 170.11% increase from a year earlier, with the FY2025 full-year figure at $112.3 million, up 55.73% from the prior year.
• Cash & Equivalents advanced to $157.8 million in Q1 2026 per TNGX's latest filing, from $112.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $157.8 million in Q1 2026 and bottomed at $39.3 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $61.2 million (2024), against an average of $75.1 million.
• Across the five-year window, Cash & Equivalents tumbled 58.65% in 2022 and soared 170.11% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $60.0 million in 2022, then advanced by 10.7% to $66.4 million in 2023, then climbed by 8.6% to $72.1 million in 2024, then soared by 55.73% to $112.3 million in 2025, then surged by 40.57% to $157.8 million in 2026.
• Per Business Quant, the three latest TNGX Cash & Equivalents figures stand at $157.8 million (Q1 2026), $112.3 million (Q4 2025), and $58.3 million (Q3 2025).